TABLE 2

Effects of rifampicin siHNF4 versus scrambled siRNA and rifampin on CYP2C8, CYP2C9, and CYP2C19 mRNA in primary human hepatocytes infected with scrambled siRNA or siHNF4-I

Expression of CYP2C8, CYP2C9, CYP2C19, and HNF4α mRNAs was evaluated in primary human hepatocytes in triplicate from four different donors after infection with adenovirus containing scrambled siRNA or siHNF4-I in the presence of 0.2% DMSO or 10 μM rifampicin. Data are expressed as fold induction over the DMSO controls and represent the mean ± S.D. of the four donors. Values were compared using Mann-Whitney tests.

Treatment	HNF4		2C8		2C9		2C19
Treatment	DMSO	Rif	DMSO	Rif	DMSO	Rif	DMSO	Rif
SCR	1.00 ± 0.00	1.06 ± 0.11	1.00 ± 0.00	6.58 ± 1.79^a	1.00 ± 0.00	3.00 ± 0.70^a	1.00 ± 0.00	1.84 ± 0.31^a
siHNF4	0.31 ± 0.09^b	0.40 ± 0.10^a,b	0.47 ± 0.06^b	1.09 ± 0.45^a,b	0.45 ± 0.14^b	0.63 ± 0.14^b	0.57 ± 0.15^b	0.66 ± 0.24^b

SCR, scrambled; Rif, rifampin.
↵a Values from cells treated with rifampicin significantly higher than those treated with DMSO for cells infected with scrambled siRNA or siHNF4-I, p < 0.05.
↵b Values from cells treated with siHNF4-I significantly lower than those treated with SCR siRNA for either DMSO or rifampicin controls, p < 0.05.